Articles

Export this record

Export selected records

Export record to excel

File type to download

Beta version

Record title

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

Record identifier

TN_cdi_proquest_journals_1683584578

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

ACCESS
https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1683584578

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

Full title

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2015, Vol.16 (6), p.686-694

Record Identifier

TN_cdi_proquest_journals_1683584578

Language

English

Formats

Publication information

Publisher

Identifiers

PRIMARY IDENTIFIERS

Record Identifier

TN_cdi_proquest_journals_1683584578

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1683584578

OTHER IDENTIFIERS

ISSN

E-ISSN

DOI

How to access this item

Online

1 item

How to access?

Login with a Library card